»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀåÀº 2023-2028³â 22¾ï 6,470¸¸ ´Þ·¯·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 6.78%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº PAHÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ½ÉÇ÷°üÁúȯÀÇ À§Çè ¿ä¼Ò Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ
2024³â
Á¾·á ¿¬µµ
2028³â
¿¹Ãø ±â°£
2024-2028³â
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
Àü³â ´ëºñ[2024³â]
6.23%
CAGR
6.78%
ÁõºÐ ±Ý¾×
22¾ï 6,470¸¸ ´Þ·¯
ÀÌ º¸°í¼´Â ÇâÈÄ ¸î ³â°£ Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÒ ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î PAH¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú ¹ßÀü°ú ½ÅÁ¦Ç° Ãâ½Ã, PAH Ä¡·áÁ¦ÀÇ ½ÂÀÎ Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå »óȲ
½ÃÀå »ýŰè
½ÃÀåÀÇ Æ¯Â¡
¹ë·ùüÀÎ ºÐ¼®
Á¦3Àå ½ÃÀå ±Ô¸ð Æò°¡
½ÃÀå Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð 2023³â
½ÃÀå Àü¸Á 2023-2028³â
Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ¼¼°è ½ÃÀå 2018-2022³â
Åõ¿© °æ·Îº° ºÎ¹® ºÐ¼® 2018-2022³â
ÀÛ¿ë±â¼º° ºÎ¹® ºÐ¼® 2018-2022³â
Áö¿ªº° ºÎ¹® ºÐ¼® 2018-2022³â
±¹°¡º° ºÎ¹® ºÐ¼® 2018-2022³â
Á¦5Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
±¸¸ÅÀÚÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô Âü¿©¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀïÀÇ À§Çù
½ÃÀå »óȲ
Á¦6Àå ½ÃÀå ¼¼ºÐÈ : Åõ¿© °æ·Îº°
½ÃÀå ¼¼ºÐÈ
ºñ±³ : Åõ¿© °æ·Îº°
°æ±¸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
ÁÖ»ç : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
ÈíÀÔ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
½ÃÀå ±âȸ : Åõ¿© °æ·Îº°
Á¦7Àå ½ÃÀå ¼¼ºÐÈ : ÀÛ¿ë±â¼º°
½ÃÀå ¼¼ºÐÈ
ºñ±³ : ÀÛ¿ë±â¼º°
ÇÁ·Î½ºÅ¸»çÀÌŬ¸° À¯»çü : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
¿£µµÅÚ¸° ¼ö¿ëü ±æÇ×Á¦(ERA) : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
Æ÷½ºÆ÷µð¿¡½ºÅ×¶óÁ¦(PDE) ¾ïÁ¦Á¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
°¡¿ë¼º ±¸¾Æ´Ò·¹ÀÌÆ® »çÀÌŬ·¹ÀÌÁî ÀÚ±ØÁ¦(SGCS) : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
½ÃÀå ±âȸ : ÀÛ¿ë±â¼º°
Á¦8Àå °í°´ »óȲ
Á¦9Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
ºñ±³ : Áö¿ªº°
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦10Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå ±âȸ¡¤¾ïÁ¦¿äÀÎ
Á¦11Àå °æÀï »óȲ
°³¿ä
°æÀï »óȲ
È¥¶õ »óȲ
¾÷°è ¸®½ºÅ©
Á¦12Àå °æÀï ºÐ¼®
±â¾÷ °³¿ä
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
Aerami Therapeutics Holdings Inc.
Asklepion Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Co. Ltd.
Eiger BioPharmaceuticals Inc.
Gilead Sciences Inc.
GlaxoSmithKline Plc
Johnson and Johnson Services Inc.
Lupin Ltd.
Merck and Co. Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corp.
Á¦13Àå ºÎ·Ï
ksm
The pulmonary arterial hypertension (PAH) drugs market is forecasted to grow by USD 2264.7 mn during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the pulmonary arterial hypertension (PAH) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of PAH, growing geriatric population, and increasing risk factors for cardiovascular diseases.
Technavio's pulmonary arterial hypertension (PAH) drugs market is segmented as below:
Market Scope
Base Year 2024
End Year 2028
Series Year 2024-2028
Growth Momentum Accelerate
YOY 2024 6.23%
CAGR 6.78%
Incremental Value $2264.7 mn
By Route Of Administration
Oral
Injectable
Inhalation
By Action Mechanism
Prostacyclin analogs
Endothelin receptor antagonists (ERAs)
Phosphodiesterase (PDE) inhibitors
Soluble guanylate cyclase stimulators (SGCSs)
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the increasing awareness regarding PAH as one of the prime reasons driving the pulmonary arterial hypertension (PAH) drugs market growth during the next few years. Also, growing technological advancements and new product launches and rising approval of PAH drugs will lead to sizable demand in the market.
The report on the pulmonary arterial hypertension (PAH) drugs market covers the following areas:
Pulmonary arterial hypertension (PAH) drugs market sizing
Pulmonary arterial hypertension (PAH) drugs market forecast
Pulmonary arterial hypertension (PAH) drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary arterial hypertension (PAH) drugs market vendors that include Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca PLC, Bayer AG, Daiichi Sankyo Co. Ltd., DR Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc.. Also, the pulmonary arterial hypertension (PAH) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Market Segmentation by Action Mechanism
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Market Landscape
2.1 Market ecosystem
Parent Market
Data Table on - Parent Market
2.2 Market characteristics
Market characteristics analysis
2.3 Value chain analysis
3 Market Sizing
3.1 Market definition
Offerings of companies included in the market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Chart on Global - Market size and forecast 2023-2028 ($ million)
Data Table on Global - Market size and forecast 2023-2028 ($ million)
Chart on Global Market: Year-over-year growth 2023-2028 (%)
Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2018 - 2022
Historic Market Size - Data Table on Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2018 - 2022 ($ million)
4.2 Route of Administration segment analysis 2018 - 2022
Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
4.3 Action Mechanism segment analysis 2018 - 2022
Historic Market Size - Action Mechanism Segment 2018 - 2022 ($ million)
4.4 Geography segment analysis 2018 - 2022
Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country segment analysis 2018 - 2022
Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration
6.1 Market segments
Chart on Route of Administration - Market share 2023-2028 (%)
Data Table on Route of Administration - Market share 2023-2028 (%)
6.2 Comparison by Route of Administration
Chart on Comparison by Route of Administration
Data Table on Comparison by Route of Administration
6.3 Oral - Market size and forecast 2023-2028
Chart on Oral - Market size and forecast 2023-2028 ($ million)
Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Chart on Oral - Year-over-year growth 2023-2028 (%)
Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Injectable - Market size and forecast 2023-2028
Chart on Injectable - Market size and forecast 2023-2028 ($ million)
Data Table on Injectable - Market size and forecast 2023-2028 ($ million)
Chart on Injectable - Year-over-year growth 2023-2028 (%)
Data Table on Injectable - Year-over-year growth 2023-2028 (%)
6.5 Inhalation - Market size and forecast 2023-2028
Chart on Inhalation - Market size and forecast 2023-2028 ($ million)
Data Table on Inhalation - Market size and forecast 2023-2028 ($ million)
Chart on Inhalation - Year-over-year growth 2023-2028 (%)
Data Table on Inhalation - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Route of Administration
Market opportunity by Route of Administration ($ million)
Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Action Mechanism
7.1 Market segments
Chart on Action Mechanism - Market share 2023-2028 (%)
Data Table on Action Mechanism - Market share 2023-2028 (%)
7.2 Comparison by Action Mechanism
Chart on Comparison by Action Mechanism
Data Table on Comparison by Action Mechanism
7.3 Prostacyclin analogs - Market size and forecast 2023-2028
Chart on Prostacyclin analogs - Market size and forecast 2023-2028 ($ million)
Data Table on Prostacyclin analogs - Market size and forecast 2023-2028 ($ million)
Chart on Prostacyclin analogs - Year-over-year growth 2023-2028 (%)
Data Table on Prostacyclin analogs - Year-over-year growth 2023-2028 (%)
7.4 Endothelin receptor antagonists (ERAs) - Market size and forecast 2023-2028
Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2023-2028 ($ million)
Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2023-2028 ($ million)
Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2023-2028 (%)
Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2023-2028 (%)
7.5 Phosphodiesterase (PDE) inhibitors - Market size and forecast 2023-2028
Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2023-2028 ($ million)
Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2023-2028 ($ million)
Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2023-2028 (%)
Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2023-2028 (%)
7.6 Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2023-2028
Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2023-2028 ($ million)
Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2023-2028 ($ million)
Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2023-2028 (%)
Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Action Mechanism
Market opportunity by Action Mechanism ($ million)
Data Table on Market opportunity by Action Mechanism ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2023-2028 (%)
Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Chart on North America - Market size and forecast 2023-2028 ($ million)
Data Table on North America - Market size and forecast 2023-2028 ($ million)
Chart on North America - Year-over-year growth 2023-2028 (%)
Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Chart on Europe - Market size and forecast 2023-2028 ($ million)
Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Chart on Europe - Year-over-year growth 2023-2028 (%)
Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Chart on Asia - Market size and forecast 2023-2028 ($ million)
Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Chart on Asia - Year-over-year growth 2023-2028 (%)
Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Chart on US - Market size and forecast 2023-2028 ($ million)
Data Table on US - Market size and forecast 2023-2028 ($ million)
Chart on US - Year-over-year growth 2023-2028 (%)
Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Chart on UK - Market size and forecast 2023-2028 ($ million)
Data Table on UK - Market size and forecast 2023-2028 ($ million)
Chart on UK - Year-over-year growth 2023-2028 (%)
Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Chart on Germany - Market size and forecast 2023-2028 ($ million)
Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Chart on Germany - Year-over-year growth 2023-2028 (%)
Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Chart on Canada - Market size and forecast 2023-2028 ($ million)
Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Chart on Canada - Year-over-year growth 2023-2028 (%)
Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Chart on Japan - Market size and forecast 2023-2028 ($ million)
Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Chart on Japan - Year-over-year growth 2023-2028 (%)
Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Opportunity/Restraints
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Impact of drivers and challenges in 2023 and 2028
10.4 Market opportunities/restraints
11 Competitive Landscape
11.1 Overview
11.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
11.3 Landscape disruption
Overview on factors of disruption
11.4 Industry risks
Impact of key risks on business
12 Competitive Analysis
12.1 Companies profiled
12.2 Market positioning of companies
Matrix on companies position and classification
12.3 Aerami Therapeutics Holdings Inc.
Aerami Therapeutics Holdings Inc. - Overview
Aerami Therapeutics Holdings Inc. - Product / Service
Aerami Therapeutics Holdings Inc. - Key offerings
12.4 Asklepion Pharmaceuticals LLC
Asklepion Pharmaceuticals LLC - Overview
Asklepion Pharmaceuticals LLC - Product / Service
Asklepion Pharmaceuticals LLC - Key offerings
12.5 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
12.6 Bayer AG
Bayer AG - Overview
Bayer AG - Business segments
Bayer AG - Key news
Bayer AG - Key offerings
Bayer AG - Segment focus
12.7 Daiichi Sankyo Co. Ltd.
Daiichi Sankyo Co. Ltd. - Overview
Daiichi Sankyo Co. Ltd. - Product / Service
Daiichi Sankyo Co. Ltd. - Key news
Daiichi Sankyo Co. Ltd. - Key offerings
12.8 Eiger BioPharmaceuticals Inc.
Eiger BioPharmaceuticals Inc. - Overview
Eiger BioPharmaceuticals Inc. - Product / Service
Eiger BioPharmaceuticals Inc. - Key offerings
12.9 Gilead Sciences Inc.
Gilead Sciences Inc. - Overview
Gilead Sciences Inc. - Product / Service
Gilead Sciences Inc. - Key news
Gilead Sciences Inc. - Key offerings
12.10 GlaxoSmithKline Plc
GlaxoSmithKline Plc - Overview
GlaxoSmithKline Plc - Business segments
GlaxoSmithKline Plc - Key news
GlaxoSmithKline Plc - Key offerings
GlaxoSmithKline Plc - Segment focus
12.11 Johnson and Johnson Services Inc.
Johnson and Johnson Services Inc. - Overview
Johnson and Johnson Services Inc. - Business segments
Johnson and Johnson Services Inc. - Key news
Johnson and Johnson Services Inc. - Key offerings
Johnson and Johnson Services Inc. - Segment focus
12.12 Lupin Ltd.
Lupin Ltd. - Overview
Lupin Ltd. - Product / Service
Lupin Ltd. - Key news
Lupin Ltd. - Key offerings
12.13 Merck and Co. Inc.
Merck and Co. Inc. - Overview
Merck and Co. Inc. - Business segments
Merck and Co. Inc. - Key news
Merck and Co. Inc. - Key offerings
Merck and Co. Inc. - Segment focus
12.14 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
12.15 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. - Overview
Teva Pharmaceutical Industries Ltd. - Business segments
Teva Pharmaceutical Industries Ltd. - Key news
Teva Pharmaceutical Industries Ltd. - Key offerings
Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 United Therapeutics Corp.
United Therapeutics Corp. - Overview
United Therapeutics Corp. - Product / Service
United Therapeutics Corp. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
13.3 Currency conversion rates for US$
Currency conversion rates for US$
13.4 Research methodology
13.5 Data procurement
13.6 Data validation
13.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
13.8 Data synthesis
Data synthesis
360 degree market analysis
360 degree market analysis
13.10 List of abbreviations